Researchers of the University of Barcelona (UB) described a new therapeutic target, the elF2a Kinase, for the treatment of type 2 diabetes and other metabolic diseases. The study, published in the scientific journal Diabetes, was led by the group of Manuel Vázquez Carrera, researcher of the Pharmacology and Pharmacognosy Unit of the Department of Pharmacology, Toxicology and Therapeutic Chemistry of the UB and IBUB, and CIBER for diabetes and metabolic diseases (CIBERDEM). There was also the participation of the UB-IBUB groups coordinated by Santiago Vázquez and Francesc Villarroya, and the teams of Ángela Valverde (CSIC-UAM, CIBERDEM) and Walter Wahli (University of Lausanne and Nanyang Technological University).

Type 2 diabetes is a long-term illness which affects the way in which our body uses glucose. The body is unable to use it properly and that makes it to be stuck in our blood. Diabetes which is not properly controlled can create problems in circulation, heart, eyes, kidneys and other organs.

More